Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Le résumé fourni par la source

Supplementary Fig2. PGV001-induced T cell immunity as measured by ex vivo IFNγ ELISPOT assay PBMC samples were stimulated with neoantigen peptides (pools of peptides: composed of 15mer OLPs+ 9-10mer predicted Mins corresponding to each vaccine SLP) and analyzed by IFNγ ELISPOT. All data is MOG normalized. a) Line diagrams showing longitudinal changes in IFNγ secretion upon stimulation with responder neoantigen peptides in each patient. Each line represents an individual neoantigen and each dot represents an individual time-point. For definition of “Responder” neoantigen: See Materials and Methods. b) Aligned dot plot showing IFNγ secretion at baseline (Pre) induced by all 126 neoantigens used in the study for 13 patients. Horizontal dotted line depicts cut-off threshold for immunogenicity in the assay. Peptides with immunogenicity at baseline, above the dotted line, are labeled. “Immunogenic” neoantigen: See Materials and Methods. c) Line plot showing post-vaccination immune response, as measured by IFNγ release in ex vivo ELISPOT assay, by the neoantigen peptides found to be “immunogenic” at baseline in (b). d) Plot showing number of IFNγ SFCs/million PBMCs elicited by tetanus peptide at various time points in 13 patients. e) Line plots showing immune response, as measured by IFNγ release in ex vivo ELISPOT assay, elicited by mutated neoantigen peptide pools vs their wild type (WT) counterparts at Week 28 over a range of peptide concentrations. Note: For PID:016 Week 31 sample was used. f) Kaplan Meier Curve comparing OS between subjects that responded, in ex vivo ELISPOT assay, to more or less than 40% neoantigens in their vaccines. PID-017 was lost of follow up and excluded from this analysis. g) Comparing number of SFCs/million PBMCs elicited by each neoantigen in patients Alive (N=6) or Deceased (N=4) at 60-month survival follow up. Total 96 neoantigens analyzed. h) Pie chart showing proportion of neoantigens that elicited antigen specific response in patients within Alive (N=6) vs Deceased (N=4) cohorts. SFC: spot forming cells. In f-h patients that expired with no evidence of their disease recurrence are excluded. *p value indicates two-sided Student’s T-test. *** <0.001. # p value indicates Log-rank (Matel-Cox) test ### <0.001. in patients within Alive (N=6) vs Deceased (N=4) cohorts. SFC: spot forming cells. In f-h patients that expired with no evidence of their disease recurrence are excluded. *p value indicates two-sided Student’s T-test. *** <0.001. # p value indicates Log-rank (Matel-Cox) test ### <0.001.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.